Last10K.com

Ac Immune Sa (ACIU) SEC Filing 20-F Annual report for the fiscal year ending Monday, December 31, 2018

Ac Immune Sa

CIK: 1651625 Ticker: ACIU

View differences made from one year to another to evaluate Ac Immune Sa's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ac Immune Sa.

Continue

Assess how Ac Immune Sa's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ac Immune Sa's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Document And Entity Information
Balance Sheets
Statements Of Cash Flows
Statements Of Cash Flows (Parenthetical)
Statements Of Changes In Equity
Statements Of Comprehensive Loss
Statements Of Comprehensive Loss (Parenthetical)
Statements Of Loss
Basis Of Preparation
Basis Of Preparation (Details)
Capital Risk Management
Cash And Cash Equivalents And Financial Assets
Cash And Cash Equivalents And Financial Assets (Tables)
Cash And Cash Equivalents And Financial Assets, Cash And Cash Equivalents (Details)
Cash And Cash Equivalents And Financial Assets, Cash And Cash Equivalents And Short-Term Financial Assets (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Commitments And Contingencies (Tables)
Debt Obligation
Debt Obligation (Details)
Earnings Per Share
Earnings Per Share (Details)
Earnings Per Share (Tables)
Expenses By Category
Expenses By Category (Details)
Expenses By Category (Tables)
Financial Instruments And Risk Management
Financial Instruments And Risk Management (Details)
Financial Instruments And Risk Management (Tables)
General Information
General Information (Details)
Income Taxes
Income Taxes (Details)
Income Taxes (Tables)
Income Taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses And Unused Tax Credits (Details)
Other Current Receivables
Other Current Receivables (Details)
Other Current Receivables (Tables)
Post Balance Sheet Events
Post Balance Sheet Events (Details)
Prepaid Expenses And Accrued Income
Prepaid Expenses And Accrued Income (Details)
Prepaid Expenses And Accrued Income (Tables)
Property, Plant And Equipment
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Quarterly Financial Results (Unaudited)
Quarterly Financial Results (Unaudited) (Details)
Quarterly Financial Results (Unaudited) (Tables)
Related-Party Transactions
Related-Party Transactions (Details)
Related-Party Transactions (Tables)
Retirement Benefit Plan
Retirement Benefit Plan (Details)
Retirement Benefit Plan (Tables)
Retirement Benefit Plan, Actuarial Assumptions And Sensitivity Analysis (Details)
Retirement Benefit Plan, Change In Net Defined Benefit Liability (Details)
Retirement Benefit Plan, Change In Other Comprehensive Loss (Details)
Retirement Benefit Plan, Changes In Defined Benefit Obligation (Details)
Retirement Benefit Plan, Changes In Fair Value Of Plan Assets (Details)
Revenues
Revenues (Tables)
Revenues, 2015 Grant From The Michael J. Fox Foundation (Details)
Revenues, Alpha-Synuclein And Tdp-43 Pet Tracers In Ad - 2016 Agreement With Biogen (Details)
Revenues, Anti-Abeta Antibody In Ad - 2006 Agreement With Genentech (Details)
Revenues, Anti-Tau Antibody In Ad - 2012 Agreement With Genentech (Details)
Revenues, Changes In Contract Assets And Liabilities (Details)
Revenues, Contract Revenue Attributable To Licensing Arrangements (Details)
Revenues, Recognized Revenues (Details)
Revenues, Recombinant Protein Therapeutic Candidate -2017 Agreement With Essex Bio-Technology Limited (Details)
Revenues, Tau Vaccine In Ad - 2014 Agreement With Janssen Pharmaceuticals (Details)
Revenues, Tau-Pet Imaging Agent In Ad -2014 Agreement With Life Molecular Imaging (Formerly Piramal Imaging Sa) (Details)
Share Capital
Share Capital (Details)
Share Capital (Tables)
Share Capital, Initial Public Offering And Follow-On Offerings (Details)
Share Capital, Preferred Shares (Details)
Share Capital, Shelf Registration Statement (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation, Non-Vested Share Awards (Details)
Share-Based Compensation, Outstanding Options, Range Of Exercise Prices And Expiration Dates (Details)
Share-Based Compensation, Plans Outstanding (Details)
Share-Based Compensation, Weighted Average Exercise Prices (Details)
Share-Based Compensation, Weighted Average Grant Date Fair Value And Assumptions (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Trade Payables, Accrued Liabilities And Deferred Income
Trade Payables, Accrued Liabilities And Deferred Income (Details)
Trade Payables, Accrued Liabilities And Deferred Income (Tables)
Ticker: ACIU
CIK: 1651625
Form Type: 20-F Annual Report
Accession Number: 0000950103-19-003578
Submitted to the SEC: Thu Mar 21 2019 7:51:06 AM EST
Accepted by the SEC: Thu Mar 21 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aciu/0000950103-19-003578.htm